Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of
Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days
after Neuradiab administration in patients with a first or second recurrence of glioblastoma
multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant
glioma.